In this article
FDA Accelerated Approval of Epcoritamab-bysp for Follicular Lymphoma
June 2024: The Food and Drug Administration has given accelerated approval to epcoritamab-bysp (Epkinly, Genmab US, Inc.), a bispecific CD20-directed CD3 T-cell engager, for adult patients with recurrent or refractory follicular lymphoma (FL) who have undergone two or more courses of systemic therapy.
The efficacy and safety of the treatment were assessed in a clinical experiment called EPCORE NHL-1 (Study GCT3013-01; NCT03625037). This trial was open-label, meaning that both the researchers and the participants knew which treatment was being administered. It comprised 127 patients who had relapsed or refractory follicular lymphoma (FL) after receiving at least two rounds of systemic therapy.
Clinical Efficacy and EPCORE NHL-1 Study Results
The trial took place at many centers and involved different groups of patients, but all of them received the same treatment. The main measure of effectiveness and safety was determined based on a group of 127 patients who followed a 2-step increase in dosage plan. An additional group of 86 patients was studied to determine the optimal dosage schedule for mitigating cytokine release syndrome (CRS). The recommended approach involved a 3-step increase in dosage.
The primary metrics of effectiveness were the overall response rate (ORR) and duration of response (DOR), which were determined by an Independent Review Committee using the Lugano 2014 criteria. Among the 127 patients in the primary efficacy group, the overall response rate (ORR) was 82% (95% confidence interval [CI]: 74.1, 88.2), with 60% of patients attaining complete responses.
Among the participants who responded to the treatment, the estimated median duration of response (DOR) was not determined during the 14.8 months of follow-up. The confidence interval for the projected median DOR ranged from 13.7 months to not determined (NR). The Kaplan-Meier estimate for the duration of response (DOR) over a 12-month period was 68.4%, with a 95% confidence interval (CI) ranging from 57.6% to 77.0%. The effectiveness was comparable across the 86 patients who underwent the 3-step dosage escalation regimen.
Safety Profile and Management of Side Effects
The prescribing material contains a boxed warning regarding the potential occurrence of severe or deadly cytokine release syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity (ICANS). Important precautions and warnings involve the risk of severe infections and reductions in blood cell counts. The incidence of ICANS was 6.0%, while severe infections occurred in 40% of cases. Out of the 86 patients with relapsed or refractory follicular lymphoma who followed the prescribed 3-step dose regimen, 49% experienced CRS. All of these occurrences were classified as either grade 1 (45%) or grade 2 (9%).
The predominant side effects (≥20%) included local responses at the injection site, cytokine release syndrome, COVID-19 infection, exhaustion, upper respiratory tract infection, musculoskeletal pain, rash, diarrhea, fever, cough, and headache. The most prevalent laboratory abnormalities observed in Grade 3 to 4 cases were a reduction in lymphocyte count, neutrophil count, white blood cell count, and hemoglobin levels, with a frequency of at least 10%.
Recommended Dosage Schedule and Ongoing Phase 3 Research
The suggested treatment protocol is the subcutaneous administration of epcoritamab-bysp in 28-day cycles until there is evidence of disease progression or the occurrence of intolerable side effects. The recommended dosage consists of a 3-step increase schedule in Cycle 1, with doses of 0.16 mg on Day 1, 0.8 mg on Day 8, 3 mg on Day 15, and 48 mg on Day 22. For Cycles 2 and 3, the dose remains at 48 mg on Days 1, 8, 15, and 22. In Cycles 4 to 9, the dose is 48 mg on Days 1 and 15. From Cycle 10 onwards, the dose remains at 48 mg on Day 1.
This application has been granted approval using the fast approval procedure. The therapeutic efficacy of epcoritamab-bysp is now being assessed in a Phase 3 randomized study (NCT05409066), which is nearing completion with a high enrollment rate of 95%. This trial aims to evaluate the effectiveness of rituximab and lenalidomide alone or in combination with epcoritamab-bysp in patients with relapsed or refractory FL.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Susan Hau
Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy. Hau's expertise lies in cancer cell biolo…
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.